# US 2016/0257955 A1 · Methods for inducing cardiomyocyte proliferation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257955 A1
- Document ID: US20160257955A1
- Status: Published application
- Kind: A1
- Application number: 15/080,240
- Filed: 2016-03-24
- Published: 2016-09-08
- Earliest claimed: 2013-02-07
- Assignees: Children's Medical Center Corporation
- Applicants: Children's Medical Center Corporation
- Inventors: Da-Zhi Wang; Jinghai Chen
- Web page: https://patentgrep.com/patent/US20160257955A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/30: Special therapeutic applications
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/51: Specially adapted vectors
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for inducing cardiomyocyte proliferation, e.g., in vivo, by administering a composition comprising miRNA17-92 cluster oligonucleotides, e.g., miR-19a oligonucleotides, miR-19b oligonucleotides, or both miR-19a and miR-19b oligonucleotides.

## Claims

### Claim 1

A method of improving cardiac function in a subject, the method comprising:
identifying a subject in need of improving cardiac function; and
administering to the subject a therapeutically effective amount of an microRNA (miR)-19a/19b oligonucleotide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is treated with a cardiotoxic compound.

### Claim 3 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is an amount sufficient to induce cardiomyocyte proliferation.

### Claim 4 (depends on 3)

The method of claim 3, wherein the amount of cardiomyocyte proliferation is sufficient to increase cardiac contractile force, or increase the thickness of the myocardium; and wherein the method optionally includes detecting an improvement in cardiac function, an increase in cardiac contractile force, or an increase in the thickness of the myocardium.

### Claim 5 (depends on 1)

The method of claim 1, wherein the miR-19a/b oligonucleotide is a single stranded DNA or RNA that is at least 18, 19, or 20 nucleotides long, but less than 24 nucleotides long, and is at least 80% identical to SEQ ID NO:1 or 3, with 100% identity to nucleotides 1-8 of SEQ ID NO:1 or 3.

### Claim 6 (depends on 5)

The method of claim 5, wherein the miR-19a/b oligonucleotide comprises at least one modification selected from the group consisting of: 5′-phosphorylation; at least one 2′-fluoro ribose modification; and a cholesterol moiety.

### Claim 7 (depends on 5)

The method of claim 5, wherein the miR-19a/b oligonucleotide comprises SEQ ID NO:1 or 3.

### Claim 8 (depends on 1)

The method of claim 1, wherein the miR-19a/b oligonucleotide is a double stranded DNA or RNA, comprising:
a first strand comprising a sequence that is at least 80% identical to 18, 19, or 20 consecutive nucleotides of SEQ ID NO: 1 or 3, with 100% identity to nucleotides 1-8 of SEQ ID NO:1 or 3;
a second strand comprising a sequence that is complementary to the first strand; and
an optional linker therebetween.

### Claim 9 (depends on 8)

The method of claim 8, wherein the double stranded DNA or RNA comprises SEQ ID NO:2 or 4.

### Claim 10 (depends on 8)

The method of claim 8, wherein the double stranded DNA or RNA comprises at least one modification selected from the group consisting of: 5′-phosphorylation; and 2′-O-methyl ribosyl substitution at position 2 in the first strand.

### Claim 11 (depends on 1)

The method of claim 1, wherein the miR-19a/b oligonucleotide is administered locally to the heart of the subject.

### Claim 12 (depends on 1)

The method of claim 1, wherein the miR-19a/b oligonucleotide is administered using a virus; a nanoparticle or microparticle delivery; or a gelfoam.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is a post-neonatal, adolescent, or adult mammal.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject is a human.
